Saniona AB (publ) (LON: 0RQJ)

Market Cap	51.26M
Revenue (ttm)	1.96M
Net Income (ttm)	-6.41M
Shares Out	n/a
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,740
Average Volume	5,094
Open	6.24
Previous Close	n/a
Day's Range	6.24 - 6.24
52-Week Range	0.13 - 0.61
Beta	1.00
RSI	50.52
Earnings Date	Feb 27, 2025

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Pr...

• Industry: Pharmaceutical Preparations
• Founded: 2011
• Employees: 23
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RQJ

Financial Performance

In 2023, Saniona AB's revenue was 16.84 million, an increase of 10.19% compared to the previous year's 15.28 million. Losses were -95.81 million, -54.71% less than in 2022.

Financial numbers in SEK